Supernus price target lowered to $43 from $46 at Piper Sandler

Piper Sandler analyst David Amsellem lowered the firm’s price target on Supernus to $43 from $46 and keeps an Overweight rating on the shares. The firm revised EBITDA estimates to reflect lower sales contribution from antiepileptic drug Oxtellar XR following the recent generic settlement with Apotex.